APLS — Apellis Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $3.96bn
- $4.06bn
- $396.59m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -305 | -345 | -746 | -652 | -529 |
Depreciation | |||||
Non-Cash Items | 40.2 | 164 | 275 | 153 | 132 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 53.1 | 19.6 | -93.5 | -15.7 | -200 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -211 | -160 | -563 | -514 | -595 |
Capital Expenditures | -1.69 | -5.42 | -1.1 | -1.52 | -0.773 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -312 | 249 | 61.4 | 0.099 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -1.69 | -317 | 248 | 59.9 | -0.674 |
Financing Cash Flow Items | 91.6 | -23.1 | -5.79 | -5.68 | -11 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 389 | 692 | 392 | 366 | 394 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 176 | 215 | 74.7 | -88.7 | -201 |